Moderna shareholders have spent the past two weeks pricing a future that does not yet exist on any income statement. The company’s cancer vaccine collaboration with Merck has produced a genuine Phase 3 win, its CEO has sketched a far broader vision, and the stock has ridden a 678% year-to-date advance into territory where valuation itself has become a headline. Somewhere beneath all of that sits a plain seasonal flu business whose third-quarter 2026 results are due November 6 — before the opening bell, with a conference call to follow.
That date matters because the most recent leg of the rally had nothing to do with a press release. Shares climbed 3.5% as investors positioned for the seasonal vaccine franchise ahead of the quarterly update, according to media reports, with no fresh company announcement behind the move. The market raised its expectations. Whether operations can meet them is a separate ledger entry.
A 42% Risk Cut, and a Stock That Fell Anyway
The clinical anchor for the bull case arrived roughly two weeks ago, when Moderna and Merck detailed Phase 3 data from INTerpath-001. Intismeran autogene combined with KEYTRUDA cut the risk of melanoma recurrence or death by 42% versus KEYTRUDA alone, and reduced the risk of distant metastasis or death by 38%. The trial hit its primary endpoint.
Overall survival data were not yet mature — a caveat that belongs in any honest reading of the result. Positive findings on the reported endpoints do not close every clinical question.
Nor did they lift the share price. Reuters reported a sharp decline around the release, which came earlier than the planned ESMO presentation after an information leak. Analysts framed the drop as profit-taking after a months-long run. The later recovery, helped by a fuller presentation and publication in the New England Journal of Medicine, did not erase the lesson: good data and rising prices are not a fixed pair. What investors had already expected decides the reaction.
Bancel Pushes the Horizon Past Melanoma
CEO Stéphane Bancel widened the lens in an October 26 conversation with STAT, saying the personalized cancer vaccine developed with Merck could work across multiple tumor types. That is a meaningful possibility, not a demonstrated one. Anyone valuing Moderna has to keep two layers apart — the clinical results in hand and the hopes pinned on extending them.
Should investors sell immediately? Or is it worth buying Moderna?
Moderna’s own investor materials list Phase 1 results for intismeran combined with FOLFIRINOX in operable pancreatic cancer, which gives the broader development thesis something concrete to stand on. It does not license carrying the melanoma benefit over to that setting. A wider label would change the story investors tell about Moderna; until then it is an option whose weight must be measured against further trial data.
The Street Is Not Speaking With One Voice
Sell-side opinion has split along exactly that fault line. William Blair downgraded Moderna from Outperform to Market Perform on October 27, citing valuation concerns and offering no price target. A day earlier, Piper Sandler had lifted its target to $230 from $167 while keeping an Overweight rating — an explicitly positive signal.
Institutional flows leaned the same way as Piper. Media reports on ownership filings showed several funds adding substantially to their Moderna positions. Such buying demonstrates interest; like a higher target, it does not substitute for operational confirmation.
What the November Print Can and Cannot Settle
The upcoming quarterly report gives the recent optimism a concrete test. The question is not simply whether the numbers are received warmly, but whether they support the expectations for seasonal vaccine sales on which the latest advance was built.
Moderna therefore sits between a near-term commercial bet and a long-term clinical one, each demanding different evidence. The recent rebound is best read as an advance of confidence — not as its repayment. November 6 will show whether the seasonal business actually carries the optimism. The cancer thesis will be judged on its own clock, by data that do not yet exist.
Ad
Moderna Stock: Buy or Sell?! New Moderna Analysis from November 4 delivers the answer:
The latest Moderna figures speak for themselves: Urgent action needed for Moderna investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 4.
Moderna: Buy or sell? Read more here...
